ADVERSE REACTIONS
In 18 clinical studies of various formulations of clindamycin phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].
Number of patients reporting events |
# not recorded
|
|
* of 126 subjects
|
| Treatment Emergent Adverse Event | Solution | Gel | Lotion |
| n=553
| (%) | n=148 | (%) | n=160 | (%) |
| Burning | 62 | (11) | 15 | (10) | 17 | (11) |
| Itching | 36 | (7) | 15 | (10) | 17 | (11) |
| Burning/Itching | 60 | (11) | # | (–) | # | (–) |
| Dryness | 105 | (19) | 34 | (23) | 29 | (18) |
| Erythema | 86 | (16) | 10 | (7) | 22 | (14) |
| Oiliness/Oily Skin | 8 | (1) | 26 | (18) | 12* | (10) |
| Peeling | 61 | (11) | # | (–) | 11 | (7) |
Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally.
Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see WARNINGS).
Abdominal pain and gastrointestinal disturbances as well as gram-negative folliculitis have also been reported in association with the use of topical formulations of clindamycin.
|
